Axion Biosystems

Axion Biosystems is a life science company focused on solving problems related to human heart and brain activity. We tackle these problems by integrating our core technology – proprietary electronics and microfabrication methods – with biology. This capability has led us to initiate the development of products for three different markets – life science instrumentation, medical diagnostics, and implantable stimulation devices.
Our primary focus has been on the life science instrument that was commercialized in 2011, a multiwell microelectrode array (MEA) system. Currently, pharmaceutical and biotech companies, academics, and government agencies use Axion’s product to screen complex human functions and disease states in a dish, such as the arrhythmias and seizure activities that emerge between networks of human cells. Using the same core technology, we are developing a non-invasive platform that functionally images peripheral nerves and an implantable MEA that stretches and conforms to soft human tissue.
The Company received a 2012 Tibbetts Award from the Small Business Administration (SBA) based on our technological innovation. In addition, Axion has received over $5.5 million in funding from the National Institutes of Health (NIH) and the Georgia Research Alliance (GRA). We expect to continue innovating by rapidly advancing development of analytical and biological tools, bringing our customers the next-generation toolsets for safety assessment and drug screening.